- Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
In the deck
Earlier from GH Research
- GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
- GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
- GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
- GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
- GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
Later from GH Research
- GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
- GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
- GH Research Announces Proposed Public Offering
- GH Research Announces Pricing of $150 Million Public Offering
- GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
Follow GH Research into a list and get an email when it puts out news.
Follow GH Research